Enhanced pathogenicity of Candida albicans pre-treated with subinhibitory concentrations of fluconazole in a mouse model of disseminated candidiasis

Authors

• Dhammika H.M.L.P. Navarathna, University of Nebraska - Lincoln
• Jacob M. Hornby, Lewis-Clark State CollegeFollow
• Natasha Hoerrmann, Lewis-Clark State College
• Anne M. Parkhurst, University of Nebraska - LincolnFollow
• Gerald E. Duhamel, University of Nebraska - LincolnFollow
• Kenneth Nickerson, University of Nebraska-LincolnFollow

Document Type

Article

Date of this Version

10-1-2005

Comments

Published in Journal of Antimicrobial Chemotherapy (2005) 56, 1156–1159.

Abstract

Objectives: To investigate the relative pathogenicity of Candida albicans treated with subinhibitory concentrations of fluconazole in a mouse model of disseminated candidiasis. Previous studies indicate that these cells secrete 10 times more farnesol than do untreated cells. In our usage, subinhibitory means a concentration which causes a prominent decrease in turbidity but still allows some cell growth. Methods: C. albicans A72 cells were grown overnight in 0–5.0 mM fluconazole, washed, and inoculated in mice by tail vein injection. Groups of 15 or 16 mice were injected with 1.3 • 10⁶cells and mortality was recorded for 7 days post-inoculation. The levels of farnesol in control and treated C. albicans were determined by GC/MS. Results: The MIC₅₀ for strain A72 was 0.125 mg/L (0.4 mM). Mice administered C. albicans pre-treated with 0.5 to 1.0mMfluconazole died 2.5 to 4 days earlier and had 2 to 4 times higher mortality rates than mice given untreated C. albicans. Fluconazole (0.5 to 1.0 mM) pre-treated cells were 4.2 to 8.5 times more lethal (P < 0.001)than untreated cells. The extracellular, membrane bound, and intracellular farnesol concentrations of cells pre-treated with 1.0 mM fluconazole were 12-, 2- and 6-times those of untreated cells. Conclusions: The effects of fluconazole on C. albicans are very concentration-dependent. The enhanced pathogenicity of fluconazole pre-treated C. albicans in mice should be relevant to the therapeutic and prophylactic use of fluconazole. Further research is needed to explore whether farnesol production by C. albicans is a virulence factor.